DEA Maintains Schedule I Status for MGM-15 and MGM-16 in the US

DEA Extends Schedule I Status for MGM-15 and MGM-16

The United States Drug Enforcement Administration (DEA) has announced its intent to continue the temporary placement of MGM-15 and MGM-16—two 7-hydroxymitragynine-related compounds—under Schedule I of the Controlled Substances Act (CSA). Published in the Federal Register on October 14, 2026, this notice maintains the highest level of regulatory restriction for these kratom analogs, following an initial temporary order from August 26, 2026. Schedule I classification imposes significant barriers to research, strict regulatory controls, and criminal penalties for unauthorized handling.

Mechanism and Regulatory Context

Schedule I status under the CSA is reserved for substances deemed to have a high potential for abuse, no currently accepted medical use in treatment in the United States, and a lack of accepted safety for use under medical supervision. The DEA’s notice clarifies that the renewed scheduling is a procedural move to distinguish MGM-15 and MGM-16 from mitragynine pseudoindoxyl, another kratom-related compound addressed separately in response to a recent Department of Health and Human Services (HHS) letter dated October 6, 2026. The temporary scheduling order applies not only to the base compounds but also to their isomers, esters, ethers, salts, and related chemical forms.

This action is not a final scheduling decision but a continuation of temporary controls, which can last up to two years with a possible one-year extension, pending further evaluation and potential permanent scheduling. During this period, the DEA retains the authority to enforce administrative, civil, and criminal penalties for any unauthorized manufacture, distribution, research, or possession of MGM-15 and MGM-16.

Policy and Research Implications

The continued Schedule I status for MGM-15 and MGM-16 has immediate and concrete implications for researchers, clinicians, and industry stakeholders. Researchers seeking to study these compounds must navigate the DEA’s Schedule I registration process, which involves extensive security, recordkeeping, and reporting requirements, as well as institutional review and federal oversight. This process is resource-intensive and has historically limited the number of institutions able or willing to pursue research on Schedule I substances.

• Clinical trials and preclinical research: Any clinical or preclinical research on MGM-15 or MGM-16 must be conducted under an approved Schedule I registration, which can delay or deter scientific investigation.
• Commercial development: No pharmaceutical or supplement development involving these compounds can proceed without significant regulatory hurdles, effectively halting commercial activity in the near term.
• Legal exposure: Unauthorized handling, even for analytical or instructional purposes, carries risk of severe penalties, deterring both academic and private sector engagement.

Notably, the DEA’s decision to separate the scheduling process for MGM-15 and MGM-16 from mitragynine pseudoindoxyl reflects a more granular approach to kratom-related compounds, suggesting that federal agencies are closely monitoring the proliferation of novel mitragynine analogs. This specificity may signal future regulatory actions targeting other emerging substances in the kratom chemical family.

Risks, Unknowns, and Real-World Impacts

Maintaining Schedule I status for MGM-15 and MGM-16 sustains significant barriers to scientific understanding of their pharmacology, safety, and potential therapeutic value. While the DEA cites potential for abuse and lack of accepted medical use, the limited availability of peer-reviewed research on these specific compounds means that risk assessments are largely extrapolated from related substances rather than direct empirical evidence.

A concrete example of a real failure mode in this regulatory approach is the chilling effect on basic research: when similar compounds have been placed in Schedule I, even well-resourced academic centers have struggled to maintain compliance, leading to project abandonment or diversion of research focus to less regulated substances. This can inadvertently slow the generation of safety data that regulators themselves rely on for future scheduling decisions.

Additionally, the continued lack of differentiation between potentially harmful analogs and those with unique pharmacological profiles may obscure important distinctions relevant to public health and policy. The absence of a clear pathway for rescheduling or compassionate access further complicates the landscape for clinicians and patients interested in novel approaches to pain or addiction management, where kratom analogs have been the subject of anecdotal and preliminary scientific interest.

Looking Ahead: Regulatory and Research Outlook

The DEA’s decision to maintain Schedule I status for MGM-15 and MGM-16 is likely to persist for the foreseeable future, barring new scientific evidence or a shift in federal policy toward kratom and its analogs. Stakeholders should anticipate continued legal risk and regulatory scrutiny, with limited prospects for clinical development or commercial activity involving these substances in the near term.

However, the procedural separation of scheduling actions for closely related compounds suggests that federal agencies are increasingly attentive to the nuances of emerging psychoactive substances. For researchers, this underscores the importance of proactive engagement with regulators and the need for robust, first-party safety and efficacy data to inform future scheduling decisions. For policymakers, the current approach highlights the tension between precautionary scheduling and the need to facilitate research that could clarify both risks and therapeutic potential.

How we research: This article was written and reviewed by Dr. Alex J. Morgan (PhD, Regulatory Science), with primary source verification from the Federal Register (2026-10-14). Reviewed on 2026-10-15.